Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,719
  • Shares Outstanding, K 14,289
  • Annual Sales, $ 10 K
  • Annual Income, $ -4,050 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.96
  • Price/Sales -2,071.90
  • Price/Cash Flow N/A
  • Price/Book 6.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3900 +0.72%
on 03/18/26
1.7400 -19.54%
on 02/26/26
-0.2500 (-15.15%)
since 02/18/26
3-Month
1.3900 +0.72%
on 03/18/26
2.3550 -40.55%
on 12/19/25
-0.8800 (-38.60%)
since 12/18/25
52-Week
1.3900 +0.72%
on 03/18/26
9.1900 -84.77%
on 07/14/25
-1.5700 (-52.86%)
since 03/18/25

Most Recent Stories

More News
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options...

DARE : 1.4000 (-3.45%)
Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s health...

DARE : 1.4000 (-3.45%)
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...

DARE : 1.4000 (-3.45%)
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women

Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital...

DARE : 1.4000 (-3.45%)
Biotech’s New Edge: 5 Companies Mastering "How" We Dose

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. VANCOUVER – Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by 2034 as industry...

MOOD.CN : 0.7000 (+27.27%)
WST : 239.00 (-0.18%)
PODD : 230.28 (-0.09%)
DOSEF : 0.3889 (-27.70%)
LPCN : 7.30 (-4.82%)
DARE : 1.4000 (-3.45%)
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital...

DARE : 1.4000 (-3.45%)
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) --  Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...

DARE : 1.4000 (-3.45%)
Daré Bioscience Receives $3.6 Million in Additional Grant Funding

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...

DARE : 1.4000 (-3.45%)
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports...

DARE : 1.4000 (-3.45%)
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science...

DARE : 1.4000 (-3.45%)

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.5235
2nd Resistance Point 1.4948
1st Resistance Point 1.4474
Last Price 1.4000
1st Support Level 1.3713
2nd Support Level 1.3426
3rd Support Level 1.2952

See More

52-Week High 9.1900
Fibonacci 61.8% 6.2104
Fibonacci 50% 5.2900
Fibonacci 38.2% 4.3696
Last Price 1.4000
52-Week Low 1.3900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar